Halozyme withdraws $2.1 bln buyout offer for Evotec
Updates shares in paragraph 2, adds Evotec comment in paragraph 5, analyst comment in paragraph 7
By Sriparna Roy
Nov 22 (Reuters) -Halozyme Therapeutics HALO.O has pulled its proposal to buy Evotec SE EVTG.DE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday.
Shares of Halozyme rose 4.70% to $47.80, while the U.S.-listed stock of Evotec tumbled 19.63% to $4.30.
"To date, Evotec has been unwilling to engage with us to explore a potential combination, and a company spokesperson has publicly commented that its goal is to remain an independent company," said Halozyme CEO Helen Torley.
It also said requests to meet and engage with Iris Löw-Friedrich, chairwoman of Evotec's supervisory board, were not accepted.
Evotec continues to have strong conviction in the company's standalone strategy, which is expected to accelerate growth, strengthen its long-term profitability and deliver significant value to shareholders, it said in a statement.
Halozyme's stock has fallen more than 15% since on Nov. 14 when the company disclosed its offer to buy Evotec at 11 euros per share.
Due to the large amount of cash required and the need to obtain a considerable amount of long-term debt to complete the deal, investors had looked warily at the attractiveness of the bid for Halozyme, said Benchmark analyst Robert Wasserman.
Triton was also exploring a potential buyout of Evotec, Bloomberg News reported earlier this month, after the private-equity firm confirmed a stake of nearly 10% in the company.
Evotec collaborates with biotech companies through research alliances and partnerships to help with drug development.
Shares of the German company have fallen close to 60% so far this year, as it comes under pressure from a weak market for drug development and research.
($1 = 0.9587 euros)
Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath and Sriraj Kalluvila
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
